You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Constellation Pharmaceuticals appoints Keith E. Dionne as chief executive

It looks like a straight-up swap between Boston venture capital firm Third Rock Ventures and Cambridge start-up Constellation Pharmaceuticals Inc. --- Keith E. Dionne is leaving Third Rock to replace Constellation chief executive Mark A. Goldsmith, who is off to the West Coast to be a venture partner in Third Rock’s San Francisco office.

Constellation looks to develop disease treatments from epigenetics, the study of molecular changes in cells that can activate or deactivate genes without affecting the underlying DNA code. To date, the company has raised more than $70 million from investors including Third Rock.

Continue reading below

Goldsmith will continue his involvement with Constellation as executive chairman of its board of directors, the company said in a press release.

Dionne joins Constellation from Third Rock, where he served as an entrepreneur-in-residence. Previously, he was chief executive at Surface Logix Inc.

Before entering the private sector, Goldsmith, an M.D., practiced medicine on the faculty of the University of California-San Francisco School of Medicine, Third Rock noted in a press release of its own.

Chris Reidy can be reached at
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of